Antihypertensive Medications and the Risk of Incident Type 2 Diabetes
Response to Taylor et al.
- Aidar R. Gosmanov, MD, PHD, DMSC1,
- Stephanie Connelly, MD, MPH1,
- James B. Lewis, Jr., MD1 and
- Niyaz R. Gosmanov, MD23
- 1Department of Medicine, Division of General Internal Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
- 2Department of Medicine, VA Medical Center, Oklahoma City, Oklahoma
- 3Department of Medicine, Endocrine Section, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
- Address correspondence to Aidar R. Gosmanov, MD, PhD, DMSc, Department of Medicine, 842 Jefferson Ave., Room A601, University of Tennessee Health Science Center, Memphis, TN 38103. E-mail: agosmano{at}utmem.edu
Taylor et al. (1) reported that antihypertensive regimens containing either β-blockers or thiazide diuretics confer a greater risk of new diabetes when compared with ACE inhibitors or calcium channel blockers (CCBs). However, we feel that the interpretation of data provided by the authors warrants further discussion. It is unclear what medication classes were included in the “other” category for each cohort. The Nurse’s Health Study (NHS) I …
